{"DataElement":{"publicId":"3237467","version":"1","preferredName":"Non-Protocol Agent Received Type","preferredDefinition":"the type or name of  the non-protocol agent received.","longName":"2200503v1.0:3237461v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2200503","version":"1","preferredName":"Non-Protocol Agent Received","preferredDefinition":"information related to the non-protocol agent received.","longName":"NPROT_AGT_RECD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2207028","version":"1","preferredName":"Non-Protocol Agent","preferredDefinition":"Treatment not specified in a protocol.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25590:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Protocol","conceptCode":"C25590","definition":"Treatment not specified in a protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-15C8-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2184327","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"Received","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1F66-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F17DD1B9-F77A-247F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3237461","version":"1","preferredName":"Non-Protocol Agent Type","preferredDefinition":"The type or name of the non-protocol agent.","longName":"3237461v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Pemetrexed","valueDescription":"Pemetrexed","ValueMeaning":{"publicId":"3237462","version":"1","preferredName":"Pemetrexed","longName":"3237462","preferredDefinition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6570-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3F78E39-6589-13D6-E040-BB89AD432B2B","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"ONEDATA","dateModified":"2011-05-23","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3F78E39-65AF-13D6-E040-BB89AD432B2B","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"ONEDATA","dateModified":"2011-05-23","deletedIndicator":"No"},{"value":"Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3F78E39-65D5-13D6-E040-BB89AD432B2B","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"ONEDATA","dateModified":"2011-05-23","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2839905","version":"1","preferredName":"Other","longName":"2839905","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635B8107-2331-1337-E040-BB89AD432C60","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3F78E39-65DF-13D6-E040-BB89AD432B2B","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"ONEDATA","dateModified":"2011-05-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6559-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"CAMPBELB","dateModified":"2011-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If yes, please specify","type":"Preferred Question Text","description":"If yes, please specify","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65E9-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"CAMPBELB","dateModified":"2011-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}